Rabies – a viral disease spread through an animal bite – has had an effective vaccine for more than a century. Yet people continue to die from it. Rabies kills nearly every known person that shows clinical signs of it, making it arguably one of the world’s deadliest infectious diseases.
Africa accounts for 36.4% of the 59,000 rabies deaths in humans annually. In Kenya, rabies is endemic and has been estimated to cause 2,000 deaths annually.
The country is implementing a strategy to end human deaths from rabies by 2030, starting with select pilot counties and progressively extending to the rest of the country.
Kenya’s rabies elimination strategy, launched in 2014, combines mass dog vaccination, prompt provision of rabies vaccines, public education, and enhanced surveillance of the disease in animal and human populations. But, as in many other developing countries, progress is slow. The obstacles include low levels of political commitment, partly owing to the absence of data on the true public health impact of the disease.
In the past few years, many countries have strengthened rabies control efforts by scaling mass dog vaccination programmes. They have also provided pre-exposure and post-exposure vaccines and educated communities about rabies. Most industrialised countries have eliminated rabies from domestic dog populations.
Apart from these interventions, an important aspect of ending deaths from rabies is ensuring that healthcare workers are aware of the disease, and knowledgeable about what to do. In our recent study we set out to determine levels of awareness about rabies and its management among healthcare workers in south eastern Kenya, a region with high numbers of rabies cases.
We found that many were ill-prepared to diagnose the disease in all its forms. Fewer than a quarter knew about World Health Organization (WHO) categorisation of bite wounds. Few were conversant with international guidelines on the use of post-exposure vaccines.
We also noticed stockouts of effective vaccine and immunoglobulin.
Our study highlights opportunities to tailor healthcare training programmes – preservice and then continuous – for rabies elimination. The emphasis should be on prevention and control.
Our study
Man’s best friend, the domestic dog, is the primary source of human cases of rabies. Following a risky bite, two critical steps need to be taken in quick succession to prevent disease and death.
First, the wound needs to be washed thoroughly with clean running water and soap for at least 15 minutes.
This should be followed by an injection of rabies vaccine on the day of the bite.
Multiple injections over the course of one month must follow. In the case of a severe bite, the patient would need immunoglobulin as well as the vaccine.
The reduction of risk exposure to rabies depends on the type of treatment received at a health facility. A person bitten by a dog carrying rabies is more likely to develop the disease if the wound isn’t cared for properly and if they don’t receive the rabies vaccine (and immunoglobulin for severe exposure). This can be due to a lack of awareness of bite management by healthcare workers, unavailability of rabies vaccines and immunoglobulin, or availability of poor quality vaccines.
We visited 42 health facilities, and interviewed 73 healthcare workers. They included medical officers, nurses, clinical officers, pharmacists, pharmacy and laboratory technologists, and public health officers.
Many of the healthcare workers didn’t know that encephalitis – inflammation of the brain – is a differential diagnosis for rabies. They therefore didn’t suspect rabies in patients with encephalitis. Less than a quarter of the healthcare workers were aware of the WHO categorisation of bite wounds that guides the use of post-exposure prophylaxis. One in 12 reported they knew the indication of rabies immunoglobulin.
In addition, healthcare workers were not fully informed about the latest WHO recommendations on the appropriate treatment of patients presenting with dog bites.
A good example is route of administration of the vaccine. WHO has recommended injection within the layers of the skin rather than injecting the vaccine into muscles. By adopting this dose-saving route, the healthcare system could serve up to five times more bite patients for the same vaccine amount that treats one patient.
Thorough wound washing is also key. But only a third of the healthcare workers we spoke to said that they would do so for a category two bite – where the animal nibbles on uncovered skin or the patient presents with minor bite(s) or scratch(es) without bleeding.
For category 3 bites, in which for example the animal licks broken skin or the patient presents with single or multiple bites, 43% of the respondents reported they would clean the wound.
The stocking of vaccines was another major issue. In our study, rabies vaccines were available in only 12% of the health facilities we visited with stock-out periods reported of up to 28 weeks.
We found that none of the health facilities had rabies immunoglobulin in stock at the time of the study.
Tackling the problem
Rabies control and elimination requires a concerted effort by the government, private sector and the community. By making the rabies vaccine available for both humans and animals, and creating awareness among healthcare workers and the community, Kenya can achieve the goal of ending deaths from human rabies by 2030.
But deliberate efforts need to be made. The most important is that healthcare workers need to be fully informed about the latest best practice. Integrating mass dog vaccination, provision of rabies vaccines for humans, adopting the latest WHO recommendations, risk assessment through sharing information between the health and veterinary sectors, and continuously training healthcare workers on proper management of bite patients and human rabies cases including diagnosis, are all critical for the elimination of rabies in Kenya.
Nobody should be dying of rabies. Not when there is a 100-year-old effective vaccine.
Veronicah Mbaire Chuchu receives funding from the Fogarty International Center and the Institute of Allergy and Infectious Diseases of the National Institutes of Health.
Thumbi Mwangi receives funding from Bill and Melinda Gates Foundation, USAID, World Health Organization, Wellcome Trust, UK MRC and EPSRC.
Mutono Nyamai and Philip Kitala do not work for, consult, own shares in or receive funding from any company or organisation that would benefit from this article, and have disclosed no relevant affiliations beyond their academic appointment.
This article was originally published on The Conversation. Read the original article.
